Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 17/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 14/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632423 | 0.96 | ROCK2 (0.42) | ROCK2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL12724977 | 0.93 | ROCK2 (0.45) | ROCK2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL1630266 | 0.91 | ROCK2 (0.43) | ROCK2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL1632313 | 0.90 | ROCK2 (0.44) | ROCK2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL4117268 | 0.88 | ROCK2 (0.42) | ROCK2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL4117258 | 0.86 | ROCK2 (0.41) | ROCK2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL1632016 | 0.86 | ROCK2 (0.45) | ROCK2ROCK1PDPK1 | |
| SCHEMBL4188583 | 0.86 | ROCK2 (0.47) | ROCK2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL1631606 | 0.85 | ROCK2 (0.49) | ROCK2KDM4EKMT2AROCK1 | |
| SCHEMBL1632049 | 0.84 | ROCK2 (0.47) | ROCK2ROCK1RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | claimed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | ROCK2 68/4885KDM4E 3309/4885MEN1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.